Author Archives: admin


Single-Cell Analysis of Ovarian Cortex Fails to Find Stem Cells – The Scientist

The first single-cell analysis of the human ovarian cortex revealed six main types of cells, but none of the oogonial stem cells that other researchers say they have isolated, according to a study published earlier this week (March 2) in Nature Communications. These findings are backed by the most advanced technologies, the authors say, and could put to rest a heated debate about the properties of the adult ovary that has raged for more than a decade.

The results of the experiment dont leave a lot of space for different interpretations, says Susana Chuva de Sousa Lopes, a developmental biologist at Leiden University Medical Center in the Netherlands who served on the PhD dissertation committee of coauthor Sarita Panula but was not involved in the research. It seems, she says, that cells previously identified as ovarian stem cells are in fact perivascular cells, which support blood vessel structure and help regulate blood flow.

But the discoverers of ovarian stem cells in adult mammals and other proponents of the cells existence are not convinced, citing methodological weaknesses of the new study.

Until relatively recently, scientific consensus was that a female mammals oocyte pool is fixed at birth. Adult ovaries, it was assumed, are simply unable to generate new eggs. But in 2004, Northeastern University reproductive biologist Jonathan Tilly and colleagues published findings that appeared to upend this understanding of oocyctes by presenting evidence of ovarian stem cells in adult mice.

A few years later, scientists in China claimed to have also found such germ line stem cells in the ovaries of adult mice, and showed that these cells could differentiate into functional eggs that gave rise to viable mouse pups. And in 2012, Tillys group reported the existence of germ cells in samples of human ovarian tissue, claiming that these cells could similarly generate oocytes in vitro and in vivo when injected into mice.

These findings generated a lot of publicity because they suggested that human fertility wasnt fixed after all. But the data has always been criticized, says Fredrik Lanner, an embryonic stem cell researcher at the Karolinska Institute and a coauthor on the newly published study that failed to find such stem cells.

We quite feel certain to say that in the human adult ovary in this cortex region, there is no cell that would be the oogonial stem cell.

Pauliina Damdimopoulou, Karolinska Institute

While some groups have been able to reproduce the results, others have tried and failed. Debates have erupted over methods, techniques, and protocols, and Tilly and his colleagues have published lengthy replies to those who have challenged their work. Today, the field is more or less divided into two camps regarding the existence of ovarian stem cells, says Chuva de Sousa Lopes.

To try to get to the bottom of the issue, Lanner and his collaborators harvested high-quality ovarian tissue samples from 21 healthy patients of reproductive age and isolated the ovarian cortex, the outer layer of the ovary where researchers claim to have found the elusive stem cells. The team used enzymes to break down the ovarian tissues, yielding 24,000 individual cells in total, then performed single-cell transcriptome and cell surface marker profiling, revealing six main cell types: oocytes, granulosa cells, immune cells, endothelial cells, perivascular cells, and stromal cells. None of the single-cell profiles matched those of reported ovarian stem cells.

When Lanner and colleagues stained the cells with an antibody against DDX4, a germ cell marker that is reported to select for oogonial stem cells, they found that they had instead isolated perivascular cells. The team then stained intact ovarian tissue and saw that the antibody similarly identifies perivascular cells. A comparison of the 24,000 cells to existing transcriptome data from both human fetal ovaries and the ovarian medulla, the inner region of the ovary, also failed to reveal any oogonial stem cells.

We quite feel certain to say that in the human adult ovary in this cortex region, there is no cell that would be the oogonial stem cell, says coauthor Pauliina Damdimopoulou, a cell biologist at the Karolinska Institute. She believes that other researchers have succeeded in using the DDX4 isolation technique to select and culture cells, but that what they have found are in fact perivascular cells and not oogonial stem cells.

This study again highlights that the DDX4 isolation technique is not something that can be used to isolate oogonial stem cells, University of Adelaide cell biologist Keith Jones, who was not involved in the work but coauthored a 2016 papersuggesting that the same antibody does not isolate DDX4 positive cells, writes in an email to The Scientist. It brings into question the existence of such stem cells, and leads us back to the dogma that prevailed previously in the fieldthe adult ovary does not contain oogonial stem cells.

Damdimopoulou also notes that she and her colleagues found that small, mature oocytes can slip through the filtration process, and when cultured, may appear as if they had been generated from stem cells. We think [the oocytes] were there all along from the beginning, she says. The formation of new vasculature by perivascular cells surrounding these oocytes, Chuva de Sousa Lopes suspects, could trigger dormant egg cells to become active and then mature, which might explain the results published by other labs.

Perivascular cells dont undergo meiosis, perivascular cells dont express meiotic genes, perivascular cells dont express germ cell genes.

Jonathan Tilly, Northeastern University

Others are not ready to give up on the idea of ovarian stem cells just yet. Deepa Bhartiya, a stem cell biologist at the National Institute for Research in Reproductive Health in India who was not involved with the research, has been working with ovarian stem cells since 2010 and says that they can be easily detected. Research with sheep ovarian tissues has shown that simple scraping of [the] ovary surface can show the presence of stem cells amongst the ovary surface epithelial cells, she writes in an email to The Scientist. The problem with the new study out of Sweden, Bhartiya says, is the speed at which the researchers spun their cellsmuch too slow to isolate the stem cells, which due to their small size do not pellet down at lower speeds and are therefore unknowingly discarded. Bhartiya writes that the study used novel techniques, but revealed nothing new: if sample preparation is not properone will get negative data.

Tilly argues that there are numerous methodological problems with the study. He says that at this point four independent groups have reported on the existence of oogonial stem cells, showing that the cells can generate new oocytes in both somatic ovarian tissue and outside the body in culture, and that they can undergo complete meiosis, a germ cell-specific event. Perivascular cells dont undergo meiosis, perivascular cells dont express meiotic genes, perivascular cells dont express germ cell genes, he says.

What the field really needs, says Chuva de Sousa Lopes, is more communication among researchers. The scientists that claim there are stem cells in the ovary and the scientists that are against that are somehow not really talking to each other, she says. I wish there would be more open dialogue, because sooner or later all these populations [of cells] will be clarified . . . and things will be more clear.

M. Wagner et al., Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells,Nat Commun,doi:10.1038/s41467-020-14936-3, 2020.

Amy Schleunes is an intern atThe Scientist. Email her ataschleunes@the-scientist.com.

View original post here:
Single-Cell Analysis of Ovarian Cortex Fails to Find Stem Cells - The Scientist

Coronavirus: China looking at using stem cell therapy to treat severe cases – The Straits Times

BEIJING (XINHUA) - Chinese researchers are studying the use of stem cell technology in the treatment of people critically ill with the coronavirus, the Science and Technology Daily reported.

Four Covid-19 patients who received stem cell treatment while in a serious condition have been discharged from hospital after recovering, and the clinical trial of the therapy will be further expanded, Vice-Minister of Science and Technology Xu Nanping, was cited by the paper as saying.

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells. They can become cells of the blood, heart, lungs or other body parts.

Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation, and inhibiting inflammatory response, experts say.

Stem cell therapy has also been used in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in treating Covid-19 in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration. Approvals by the ethics committee, and clinical observation and evaluation are in progress.

Another research team from the fifth medical centre of the Chinese PLA General Hospital is cooperating with hospitals and institutions in Wuhan - the epicentre of the epidemic - and northern China's Tianjin municipality to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating Covid-19 patients.

A research team at the School of Medicine of the Tongji University is studying universal lung stem cell therapy that can be widely used in the epidemic control. The therapy is expected to enter the clinical stage soon.

Professor Zuo Wei, head of the research team and the chief scientist of a national key research project on stem cells, said that the research now mainly focuses on improving the condition of critically ill Covid-19 patients.

He explained that when the patients are in a severe condition, the cause of deterioration and even death is the "inflammatory storm", when the human immune system is over-activated by the infection.

That will damage the lungs and impair breathing. Some severe patients may have respiratory failure.

"Lung inflammation and injury are the focus of the treatment of severe patients," Prof Zuo said.

The damage to lung tissue can be fatal, and stem cell therapy is expected to help repair the damage, Prof Zuo added.

Currently, three kinds of stem cells - mesenchymal, lung and embryonic stem cells - are used in treatments. Researchers usually inject stem cell products into the lungs.

Stem cells can improve the immune microenvironment in the lungs and reduce the risk of pulmonary failure caused by inflammation.

Stem cells have the potential of self-renewal and differentiation, and can develop into corresponding functional cells and alveoli, and then repair the damaged tissue, Prof Zuo said.

However, the wider use of stem cell technology to treat Covid-19 is still some time away.

The safety and effectiveness of a new drug or therapy need to be verified with sufficient clinical trials, Prof Zuo stressed.

Read more:
Coronavirus: China looking at using stem cell therapy to treat severe cases - The Straits Times

Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks – NBCSports.com

The Angels announced that starter Griffin Canning is getting a biological injection in his ailing elbow and will be re-evaluated in 3-4 weeks time. Canning was recently diagnosed with both UCL and joint issues in his pitching elbow.

The phrasing of the announcement is interesting. The word biological generally leads me in two different directions with this sort of injury. Many baseball players have been treated with platelet-rich plasma (PRP) injections for a variety of issues in recent years, but the Angels have also used stem cell injections to try to treat UCL woes.

Andrew Heaney, Garrett Richards and Shohei Ohtani all got stem cell treatments for their elbows. All three also eventually wound up getting Tommy John surgery. Im not willing to go as far as the LA Times article did in condemning the treatments as useless, seeing as a sample size of three is rather small. Theyre also not the only players who have ever been treated with stem cells. CC Sabathia, for instance, got a stem cell injection for his bad knee.

Regardless of what the treatment is or isnt, its a positive sign that Cannings injury wasnt deemed dire enough to immediately merit surgery. Canning isnt going to be ready for Opening Day either way, but if the injection works he may be able to pitch at some point this season. Goodness knows that the Angels rotation needs all hands on deck, even after the team signed both Dylan Bundy and Julio Teheran this winter.

Follow @StelliniTweets

The Indians announced via Twitter that Shane Bieber will be the teams Opening Day starter.

Its been a meteoric rise for Bieber. After a relatively pedestrian rookie year in 2018, Bieber rocketed to stardom in his sophomore campaign. The right-hander pitched to a 3.28 ERA in 214.1 innings, making the All-Star team and getting fourth place in the Cy Young Award voting along the way. Hes just 24 years old and figures to be a fixture atop the Cleveland rotation for years to come.

With Mike Clevinger still sidelined after undergoing arthroscopic surgery on his knee and Corey Kluber being traded to the Rangers, Bieber was the clear favorite for the nod.

Follow @StelliniTweets.

See the original post:
Griffin Canning to receive biological injection in elbow, will be re-evaluated in 3-4 weeks - NBCSports.com

Beating heart cells catch a ride to the International Space Station – KTVZ

Tiny heart cells are among the new batch of science experiments heading for the International Space Station Friday night, but their potential to help patients with heart disease on Earth is exponential.

SpaceXs 20th resupply mission to the station is expected to launch Friday night at 11:50 p.m. ET from Cape Canaveral Air Force Station in Florida. It includes supplies, a variety experiments and materials for ongoing research investigations. The Dragon spacecraft will also bring the European Space Agencys Bartolomeo, a commercial research platform that will be installed outside the station, according to NASA.

And nestled among the payloads are two different experiments involving cariomyocytes, or beating heart cells, grown from pluripotent stem cells. Pluripotent stem cells are ideal because they can turned in multiple cell types. In this case, they could become healthy heart cells for a patient with heart disease.

The results of the experiments could be used to generate a multitude of healthy heart cells for children and adults with various heart diseases. But they could also be used to understand heart health and the aging process in a broader context. The researchers for one of the experiments believe their study could even help astronauts with the known risks they experience during long-term spaceflight, like reduced heart function and irregular heartbeat.

Scientists already know that humans exposed to space experience changes similar to accelerated aging, so we hope the results can help us better understand and someday counteract the aging process, said Deok-Ho Kim, principal investigator for one of the experiments, and associate professor of biomedical engineering and medicine at Johns Hopkins University.

For the next month, the heart cells will undergo a unique journey to space before splashing back down in the Pacific Ocean. Heres what researchers hope to learn about the effects of zero gravity on human heart cells.

Emory University School of Medicine associate professor of pediatrics Chunhui Xu first discovered that stem cells grow faster in space by simulating the lack of gravity on Earth. She studies cardiomyocytes with the hopes of improving the hearts regenerative abilities, as well as improving congenital heart disorder treatment.

Stem cell therapies to repair damaged heart cells require at least one billion cells for each patient, Xu said. But they can take time to grow on Earth. When her experiment using simulated microgravity on Earth showed promising steps toward quickly and safely producing cardiomyocytes, Xu saw space as the ultimate proving ground.

Her experiment was chosen to fly on the space station and now she and her team hope they can confirm their ground-based observation and discover new insights as well.

She and her colleagues at Emory had to learn how to cryopreserve the cells so that they can survive the launch and trip to the space station. It also means that the astronauts can unpack everything and organize their experiment schedule, without having to jump right into the experiment for fear of the cells dying.

Once the cells are thawed, the cell cultures will grow for 21 days in the Multi-use Variable-gravity Platform experiment modules built by Techshot, Inc. Then, in an ambitious goal, the cells will actually be returned live, jettisoned in a payload that will land in the Pacific Ocean. A colleague in California will then prep them and have the live cells shipped back to Emory in Atlanta so the researchers can analyze them.

Meanwhile, during the experiment in space, a control group of cells will be put in a centrifuge in a modified gravity environment on Earth.

Weve worked together for years to bring basic and clinical science together, said Dr. Kevin Maher, director of the cardiac intensive care unit at Childrens Healthcare of Atlanta Heart Center and professor of pediatrics at Emory University. Maher is working with Xu on the experiment.

Theres a high demand on the cells themselves they need to be pure and high quality. Residual stem cells that dont turn into heart cells can cause tumors, according to previous research by Xu. More mature cells stand a better chance of becoming pure heart cells. During her ground-based experiment simulating a lack of gravity, Xu found that the cells were more mature and even expressed survival genes that could ensure cell survival. Overall, these factors would allow the cells to connect with the heart tissue better and cause less issues, Xu said.

The implications of their research could help develop a more efficient and cost-effective way to develop the heart cells on Earth for patients in need. Given that heart disease is the leading cause of death in the US, according to the CDC, the cells have great potential to treat children and adults. And the cells could also be used to test new therapies and speed up the development of safe drugs, Xu said.

The National Center for Advancing Translational Sciences is continuing its Tissue Chips in Space initiative by funding an experiment that includes a cellphone-sized chip loaded with beating heart tissue.

It starts with a similar base as the Emory experiment: pluripotent stem cells grown into cardiomyocytes. Instead of cell cultures, these are bioengineered mini tissue chips that mimic human heart function.

This allows the cells to signal and act as they would in the body, hosted on a scaffold-like bio-structure holding the tissues together. This encourages the cells inside to grow, and ultimately, this kind of structure could be used to test drugs.

We hope that this project will give us meaningful data that we can use to understand the hearts structure and how it functions, so that we can improve the health of both astronauts and those down here on Earth, said Kim.

The Johns Hopkins University researchers and their collaborating colleagues at other universities will get measurements of the tissues beating in real time. And after a month, the tissues will return to Earth. The team wants to analyze them and determine how they were affected by microgravity or if their gene expression changed. Heart tissues on Earth, identical to the ones sent to the station, will serve as a control at the University of Washington.

Some of the tissues sent to space will continue to be cultured on Earth for a week afterward in case any recovery efforts can be observed.

The entire team is excited to see the results we get from this experiment. If successful, we will embark on the second phase of the study where tissues will be sent up to the ISS once again in two years, but this time, we will be able to test a variety of drugs to see which ones will best ameliorate the potentially harmful effects of microgravity on cardiac function, said Jonathan Tsui, a member of Kims lab and a postdoctoral fellow at Johns Hopkins Universitys department of biomedical engineering.

Continued here:
Beating heart cells catch a ride to the International Space Station - KTVZ

SpaceX Dragon to launch heart cell experiment and more to space station tonight – Space.com

CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.

This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.

The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.

You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).

Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.

In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.

To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.

By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.

Related: Adidas launching new sneakers inspired by historic NASA spacesuits

Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.

Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.

To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.

Related: Showering in space: Astronaut home video shows off 'hygiene corner'

"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."

He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.

"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."

Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.

Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.

The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.

The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.

Related: Heart cells beat differently in microgravity, may benefit astronauts

Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.

"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."

In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.

Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.

Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.

"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.

And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.

The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)

If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.

Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.

View post:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com

Mutations of virus do not stymie research –

[Photo/Agencies]

Known mutations of the novel coronavirus have not affected overall progress of drug and vaccine development, and scientists will keep monitoring the virus's evolution and plan research projects accordingly, senior scientists said on Friday.

This week, Chinese scientists announced that they had discovered that the virus had evolved into two major subtypes, and detected 149 mutation points across its genomes. The L subtype, considered more aggressive, is believed to have been more prevalent during the early stages of the outbreak in Wuhan, Hubei province, than its S subtype ancestor, which is relatively more prevalent now.

Zhou Qi, deputy secretary-general of the Chinese Academy of Sciences, said the virus's mutations require further research, and China is conducting a coordinated research effort to evaluate the virus and develop a vaccine.

"All research is under control," he said. "The mutations that we now know have not affected our drug, antibody or vaccine development. We will keep monitoring the mutations the virus generates and plan related research projects accordingly."

Zheng Zhongwei, director of the Development Center for Medical Science and Technology of the National Health Commission, said China has nine ongoing research projects on vaccine development, and some will hopefully enter clinical trials in April.

The five main types of vaccines that China is working on are an inactivated vaccine, recombinant subunit vaccine, adenoviral vector vaccine, live attenuated vaccine and nucleic acid-based vaccine.

Zheng said he had not seen reports of foreign researchers working on an inactivated vaccine, which consists of virus particles that no longer have disease-producing capability. As for the recombinant and vector vaccines, he said both have moved into animal trials and their progress is on par with that of other countries.

For drug development, China has expanded the use of trial drugs and treatments, including plasma transfusion, artificial extracorporeal liver support often called liver dialysis and traditional Chinese medicine, said Sun Yanrong, deputy director of the China National Center for Biotechnology Development.

Advanced treatments such as stem cell and monoclonal antibody therapies are also being researched as a way to save patients in critical condition, she added. Chloroquine phosphate has moved from trials to clinical treatment, and no obvious side effects were found in the 285 severely ill patients taking the drug.

Scientists have expanded clinical trials for favipiravir a Japanese antiviral drug that showed promise against the virus in clinical trials in Shenzhen, Guangdong province to cover patients in Wuhan.

Doctors from hospitals in Beijing and Harbin, Heilongjiang province, are doing clinical trials for stem cell therapy and preliminary results have found the treatment safe and effective, Sun said, adding that its use will be expanded in Wuhan.

Clinical results for artificial liver support show it can significantly reduce the treatment time for critically ill patients and improve their recovery rate, she said.

Tocilizumab, a drug that suppresses overreactions of the immune system, has recently been added to the latest treatment and diagnosis guideline of the National Health Commission. It helps to inhibit a deadly medical condition called a cytokine storm an overproduction of immune cells that damages healthy tissues which is also one of the main causes of death for critically ill patients.

Sun said around 272 severely ill patients are being treated with Tocilizumab. The patients came from 14 hospitals in Wuhan, Zhou added. Early clinical data showed that 20 severely or critically ill patients had fevers lowered within a day after receiving the drug, and 19 patients had recovered within two weeks.

Contact the writers at zhangzhihao@chinadaily.com.cn

See original here:
Mutations of virus do not stymie research -

Here’s the Real Reason ‘Hawaii Five-0’ Is Getting Cancelled – Country Living

Hawaii Five-0 has been a TV staple since it debuted in 2010. Weve come to know and love Alex OLoughlins McGarrett and Scott Caan as Danno, and we cant imagine a Friday night without the duo.

But were going to have toand very soon. Hawaii Five-0 has officially been cancelled, and the series finale is slated to air in less than a month.

Its never easy to say goodbye to a hit franchise that carried on the legacy of the original with such distinction, while establishing its own signature style, said Kelly Kahl, President of CBS Entertainment. We cannot be prouder of its quality and longevity and are thankful for the passionate fan devotion it inspired.

But if it had such a passionate viewership, then why would CBS end the series? Heres everything we know.

Besides the fact that its been on 10 whole yearsa pretty lengthy amount of timeit seems there were a few behind-the-scenes factors, too. Deadline claimed Alex and Scotts contracts were up at the end of this season, which often jumpstarts an actors exit.

But the outlet also mentioned that Alex suffered a back injury years ago on set, and that he hasnt quite recovered. He reportedly had a stem cell treatment that helped, but he couldnt sign on for another round. CBS allegedly toyed with the idea of replacing Alex, but instead decided it was time to cut the cord.

The worst news out of all of this is that Hawaii Five-0s final episode will run in less than a month. The two-hour series finale will air on April 3, 2020 so we suggest stocking up on tissues now.

Yes! Apparently James Marsters (Victor Hesse), William Sadler (Jack McGarrett), and Mark Dacascos (Wo Fat) will be back to say goodbye. Theres no word on whether Grace Park or Daniel Dae Kim might return for one last time, but considering their exits seemed a little controversial were not sure we see that happening.

Hopefully they tie everything up as well as Criminal Minds did this year!

Hawaii Five-0

Season 1amazon.com

Hawaii Five-0

Season 3amazon.com

Hawaii Five-0

Season 7amazon.com

Hawaii Five-0

Season 10amazon.com

View original post here:
Here's the Real Reason 'Hawaii Five-0' Is Getting Cancelled - Country Living

Ozzy Osbourne banking on stem cells and pilates to get stage-ready – Calgary Herald

Ozzy Osbourne is banking on stem cell treatment and Pilates to help him manage his Parkinsons disease and get back on stage again.

The Paranoid hitmaker has been laid up since badly injuring himself and suffering from pneumonia last year, revealing he had Parkinsons in January and scrapping his U.S. tour last month, to head to Switzerland for treatment.

In a joint interview with U.K. TV show Good Morning Britain, Ozzy and his wife and manager Sharon opened up about the rockers recovery revealing he is undergoing stem cell treatment to lessen the effects of Parkinsons and boost his immune system.

Theres a professor there (Switzerland), Sharon said. He hasnt got a cure for Parkinsons, no one has but what he can do is he can get Ozzys immune system to here (points high), so now, if Ozzy was to catch a cold it would turn into pneumonia.

This professor has come up with a way of doing stem cells where it helps with the pain. He could hopefully get rid of Ozzys pain and then Ozzy will be healthier to deal with the Parkinsons.

The 71-year-old is not the first person in his family to undergo stem cell treatment, as his son Jack flew to Germany to receive similar therapy to help with his multiple sclerosis.

Meanwhile, the former Black Sabbath frontman has also been working hard to get fit again but thinks he will only truly feel himself again when hes back performing.

I exercise as much as I can. Ive got a trainer, I do Pilates, nurses 24/7, but the best medication I can get is being in front of an audience, which is breaking my heart to be honest, he added. I will (perform again). Absolutely. I will be up there. I have to say that. I know youre going to say what will you do if you cant do it again, thats not an option because I will do it.

More here:
Ozzy Osbourne banking on stem cells and pilates to get stage-ready - Calgary Herald

Spinal Muscular Atrophy Treatment Market to Exhibit a Spectacular CAGR of 28.9%; Growing Initiatives by Government Authorities for Pre-Diagnosis to…

Pune, March 03, 2020 (GLOBE NEWSWIRE) -- The global Spinal Muscular Atrophy Treatment Market size is expected to reach USD 14.49 billion by 2026, exhibiting a CAGR of 28.9% during the forecast period. The rising prevalence of rare diseases around the world will fuel demand for SMA treatment in the forthcoming years, which in turn will aid the growth of the market. As per the National Policy for the treatment of rare diseases, globally, around 6000 to 8000 rare diseases are estimated to exist with new rare diseases reported on a regular basis. Furthermore, 80% of all the rare diseases are genetically originated and therefore impact children inexplicably. The survey also revealed that 50% of new cases are in children and are responsible for 35% of deaths before the age of 1 year, 10% between the ages of 1 and 5 years and 12% between 5 and 15 years. Nonetheless, the growing initiatives by government authorities for pre-diagnosis will impact the Spinal Muscular Atrophy Treatment Market share positively during the forecast period, predicts our lead analysts at Fortune Business Insights.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/spinal-muscular-atrophy-treatment-market-100576

According to the report, published by Fortune Business Insights, titled Spinal Muscular Atrophy Treatment Market Size, Share and Global Trend By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Geography Forecast till 2026 the market size stood at USD 1.72 billion. The SMA Treatment Market report executes a PESTEL study and SWOT analysis to reveal the stability, restrictions, openings, and threats in the smart building market. Combined with the market analysis capabilities and knowledge integration with the relevant findings, the report has foretold the robust future growth of the SMA treatment market, and all articulated with geographical and merchandise segments. Moreover, it also shows different procedures and strategies, benefactors and dealers working in the market, explores components convincing market development, generation patterns, and following systems. Additionally, the figures and topics covered in this report are both all-inclusive and reliable for the readers.

Market Driver:

R&D Initiatives by Key Players to Spur Sales Opportunities

The surge in research and development activities for the improvement of therapies and treatment options by key players will aid the Spinal Muscular Atrophy Treatment Market growth during the forecast period. Various drug pipeline for advanced stages of clinical trials by major pharmaceutical companies will augment the healthy growth of the market. For instance, Genentech/Roches pipeline candidate of Risdiplam, which recently received a priority review from the FDA and is expected to receive a decision on approval from the FDA by May 2020. Furthermore, the growing initiatives for pre-diagnosis and positive reimbursement policies will boost the Spinal Muscular Atrophy Treatment Market trends in the foreseeable future. Moreover, the growing awareness regarding pivotal treatment options will create new opportunities for the market.

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/spinal-muscular-atrophy-treatment-market-100576

Market Restraint:

High Cost of Products to Impede Market Expansion

The cost-intensive products and high prices associated with the rare disease therapies will subsequently obstruct the growth of the market. For instance, spinraza is expected to cost US$ 750,000 for the first year and will be repriced at US$ 375,000 after that. Apart from that, Novartis rare gene therapy, Zolgensma will come at a price of US$ 2.1 million for a one-time treatment. The expensive cost of therapies will restrict the adoption of treatment for many patients, which in turn will act as a restraint for the Spinal Muscular Atrophy Treatment Market revenue.

Regional Insight:

Presence of Major Players to Influence Growth in North America

The market in North America stood at USD 854 million in 2018 and is likely to remain dominant during the forecast period. The growth in the region is attributed to the presence of prominent players in the region. The growing awareness regarding the prevalence of rare disease and pre-treatment initiatives will bolster accelerate the Spinal Muscular Atrophy Treatment Market growth in North America.

List of the Major Players Operating in the Global SMA Treatment Market Include:

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/spinal-muscular-atrophy-treatment-market-100576

Detailed Table of Content:

TOC Continued.!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/spinal-muscular-atrophy-treatment-market-100576

Have a Look at Related Reports:

Bone Growth Stimulators Market Size, Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Spinal Cord Stimulation Market Size, Share and Global Trend By Product (Implantable Pulse Generator, Radiofrequency System), Disease Indication (Failed Back Syndrome, Degenerative Disk Disease, Complex Regional Pain Syndrome, Arachnoiditis), End Users (Hospital, Ambulatory Surgical Centers, Specialty Clinics) and Geography Forecast till 2025

Spinal Devices Market Size, Share & Industry Analysis, By Product Type (Fusion Devices (Cervical Devices, Thoracolumbar Devices, Interbody Devices, and Biologics), Non-Fusion Devices (Vertebral Compression Fracture Devices, Artificial Discs, Dynamic Stabilization Devices, and Others), and Stimulation Devices) By Disease Indication (Degenerative Disc Disease, Complex Deformity, Traumas & Fractures, and Others), By End User (Hospitals & Ambulatory Surge

Spinal Fusion Devices Market Size, Share & Industry Analysis, By Product Type (Cervical Devices, Thoracolumbar Devices, Interbody Devices, and Biologics), By Disease Indication (Degenerative Disc Disease, Complex Deformity, Traumas & Fractures, and Others), By End User (Hospitals & Ambulatory Surgery Centers, Specialty Clinics and Others) and Regional Forecast, 2019-2026

Orthopedic Implants Market Size, Share & Industry Analysis, By Product (Joint Reconstruction, Spinal Implants, Trauma Implants, Dental Implants, Orthobiologics, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinsons Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2019-2026

Orthodontics Market Size, Share & Industry Analysis, By Product Type [Instruments and Supplies {Fixed (Brackets, Bands & Buccal Tubes, Archwires, and Others), and Removable (Aligners, Retainers, and Others)}], By End User (Hospitals, Dental Clinics, Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/spinal-muscular-atrophy-sma-treatment-market-9626

See original here:
Spinal Muscular Atrophy Treatment Market to Exhibit a Spectacular CAGR of 28.9%; Growing Initiatives by Government Authorities for Pre-Diagnosis to...

Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. – Physician’s Weekly

Erectile dysfunction caused by damage to the cavernous nerve (CN) is a common complication of radical prostatectomy for patients with localized prostate cancer. Various studies have investigated repair of damaged tissue and prevention of fibrosis in the corpus cavernosum using stem cell therapy. However, stem cell therapy has limitations, including insufficient nutrient and oxygen supply to transplanted stem cells. This study investigated whether stem cell/oxygen-releasing hollow microparticles (HP) were therapeutic effect on therapeutic effects on erectile dysfunction in a rat model of bilateral cavernous nerve injury (BCNI). Therapeutic effects were observed in the BCNI model at 1,2, and 4 weeks post-cavernous nerve injury. Erectile function further improved after treatment with stem cell/oxygen-releasing HP system compared treatment with only stem cells at 4 weeks. Stem cell/oxygen-releasing HP system increased cGMP level and nNOS, eNOS, a-SMA and M3 expression, while decreasing fibrosis and apoptosis in the corpus cavernosum. Our results clearly show that stem cell survival increase around transplanted stem cell/oxygen releasing hybrid system site. Taken together, an oxygen-releasing HP system supported prolonged stem cell survival, sustaining the paracrine effect of the stem cells, and consequently enhancing erectile function. These findings show promise with regard to prolonged stem cell survival in stem cell applications for various diseases and types of tissue damage.

Read the original post:
Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. - Physician's Weekly